XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Stock Based Compensation (Tables)
3 Months Ended
Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Schedule of activity related to stock options


 

Number of Options

 

 

Weighted Average Exercise Price

 

 

Weighted Average Remaining Contractual Term (Years)

 

 

Aggregate Intrinsic Value

Outstanding, January 1, 2021 

 

3,815,585

 

 

$

5.56

 

 

 

8.9

 

  $

342,551

Granted

 

1,090,000

 

 

 

2.05

 

 

 

 

 

 

218,950

Exercised

 

 

 

 

 

 

 

 

 

 

 —

Cancelled

 

 

 

 

 

 

 

 

 

Outstanding, March 31, 2021


4,905,585


 

$

4.78



 

8.7


 $

1,396,195

Exercisable, March 31, 2021

 

1,597,409

 

 

$

8.38

 

 

 

8.0

 

$

223,339

Schedule of activity related to restricted stock awards granted


 

 

Number of Shares

 

 

Weighted Average Grant Date Fair Value

 

 

Nonvested, January 1, 2021

  

 

25,645

 

 

$

10.07

 

 

Granted

 

 

165,413

 

 

 

2.42

 

 

Vested

 

 

(120,051

)

 

 

3.33

 

 

Cancelled

 

  

 

 

 

 

Nonvested, March 31, 2021

 

 

71,007

 

 

$

4.74

 

 

Schedule of activity related to restricted stock and deferred stock units granted


 

 

Number of Shares

 

 

Weighted Average Grant Date Fair Value

 

Nonvested, January 1, 2021

 

 

1,014,123

 

 

$

1.50

 

Granted

 

 

147,000

 

 

 

2.83

 

Vested

 

 

(15,675

)

 

 

1.83

 

Cancelled

 

 

 

 

 

Nonvested, March 31, 2021

 

 

1,145,448

 

 

$

1.67

 

Schedule of recognized stock compensation for equity awards


 

Three months ended

March 31,


 

2021

 

 

2020


Selling, general and administrative

$

809,547

 

 

$

547,090

 

Research and development

 

112,986

 

 

 

186,599

 

Cost of goods sold

 

19,650

 

 

 

11,176

 

Total expense  $

942,183

 

 

$ 744,865

 

Schedule of weighted average assumptions used in valuing plans


 

Three months ended

March 31, 2021

 


Three months ended

March 31, 2020


Fair value at grant date

$

1.39

 

$ 1.27

Expected volatility

79.9


113.4  

Risk-free interest rate

0.6


1.4 %

Expected holding period, in years

6.1

 


6.1

Dividend yield

 


%